Abstract:Current cancer management strategies fail to adequately treat malignancies with multivariable dose-restricting factors such as systemic toxicity and multi-drug resistance limiting therapeutic benefit, quality of life and complete long-term remission rates. The targeted delivery of a therapeutic compound aims to enhance its circulation and cellular uptake, decrease systemic toxicity and improve therapeutic benefit with disease specificity. The transferrin peptide, its receptor and their biological significance, has been widely characterised and vastly relevant when applied to targeting strategies. Utilising knowledge about the physiological function of the transferrin–transferrin receptor complex and the efficiency of its receptor-mediated endocytosis provides rationale to continue the development of transferrin-targeted anticancer modalities. Furthermore, multiple studies report an upregulation in expression of the transferrin receptor on metastatic and drug resistant tumours, highlighting its selectivity to cancer. Due to the increased expression of the transferrin receptor in brain glioma, the successful delivery of anticancer compounds to the tumour site and the ability to cross the blood brain barrier has shown to be an important discovery. Its significance in the development of cancer-specific therapies is shown to be important by direct conjugation and immunotoxin studies which use transferrin and anti-transferrin receptor antibodies as the targeting moiety. Such conjugates have demonstrated enhanced cellular uptake via transferrin-mediated mechanisms and increased selective cytotoxicity in a number of cancer cell lines and tumour xenograft animal models. In addition, incubation of chemotherapy-insensitive cancer cells with transferrin-targeted conjugates in vitro has resulted in a reversal of their drug resistance. Transferrin immunotoxins have also shown similar promise, with a diphtheria toxin mutant covalently bound to transferrin (Tf-CRM107) currently involved in human clinical trials for the treatment of glioblastoma. Despite this, the inability to translate preliminary research into a clinical setting has compelled research into novel targeting strategies including the use of nanoparticulate theory in the design of drug delivery systems. The main objective of this review is to evaluate the importance of the transferrin–transferrin receptor complex as a target for cancer therapy through extensive knowledge of both the physiological and pathological interactions between the complex and different cell types. In addition, this review serves as a summary to date of direct conjugation and immunotoxin studies, with an emphasis on transferrin as an important targeting moiety in the directed delivery of anticancer therapeutic compounds.

Research Advance on Transferrin Receptor in Hematological Malignant Tumor Treatment

Transferrin-Transferrin Receptor Mediated Initiative Targeted Therapy of Tumor

The Transferrin Receptor: Its Diagnostic Value and its Potential as Therapeutic Target

Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy

Iron Metabolism, Ferroptosis, and Lncrna in Cancer: Knowns and Unknowns

Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway

Transferrin receptor 1 targeted nanomedicine for brain tumor therapy

Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents

Iron Transporters and Ferroptosis in Malignant Brain Tumors

Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases

Tumor iron homeostasis and immune regulation

Therapeutic strategies of iron-based nanomaterials for cancer therapy

Ferritin in cancer therapy: A pleiotropic tumoraffin nanocage‐based transport

Role of Fe, Transferrin and Transferrin Receptor in Anti-Tumor Effect of Vitamin C

Recent progress of iron-based nanomaterials in gene delivery and tumor gene therapy

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Nanodrug Hijacking Blood Transferrin for Ferroptosis-Mediated Cancer Treatment

Transferrin Receptor is Associated with Sensitivity to Ferroptosis Inducers in Hepatocellular Carcinoma

Transferrin and transferrin receptors update

Transferrin-inspired iron delivery across the cell membrane using [(L2Fe)2(μ-O)] (L = chlorquinaldol) to harness anticancer activity of ferroptosis